IGF2 and neoplasm: Tumor cells with mesenchymal phenotype are resistant to the dual IGF-IR/InsR inhibitor linsitinib, due to the decreased expression of IGF2 and InsR, and phosphorylation of IGF-IR/InsR in these cells [182].